NOVEMBER 26, 2018 - A Mission Therapeutics e a AbbVie estabeleceram uma nova parceria destinada a desenvolver inibidores específicos visando enzimas de desubiquidação (n.t.: deubiquitylating enzymes) (ou DUBs) para o tratamento de doenças de Alzheimer e Parkinson.
Os DUBs são uma grande família de importantes enzimas que regulam o processo de degradação de proteínas, alguns dos quais estão envolvidos na destruição de proteínas deformadas e potencialmente tóxicas conhecidas por estarem associadas a doenças humanas.
Embora os DUBs representem um alvo terapêutico atraente para vários distúrbios, o desenvolvimento de inibidores potentes adequados para uso clínico tem sido um desafio devido a questões ligadas à especificidade e seletividade.
A Mission desenvolveu uma plataforma de descoberta focada na superação dessas limitações e na identificação de inibidores de DUB de moléculas pequenas que poderiam funcionar no cérebro, permitindo a degradação de proteínas prejudiciais.
“Há uma necessidade urgente de novos tratamentos que terão um impacto positivo na vida de pacientes com doença de Alzheimer e Parkinson. Os cientistas da Mission desenvolveram uma pesquisa inicial impressionante para o entendimento dessas doenças. Juntos, trabalharemos para promover essa ciência inicial e desenvolver terapias significativas”, disse James B. Summers, PhD, vice-presidente de pesquisa de descoberta de neurociência da AbbVie, em um comunicado de imprensa.
Sob os termos da nova parceria, a Mission e a AbbVie irão colaborar durante a fase de descoberta para identificar DUBs específicos e compostos de interesse para posterior avaliação pré-clinica.
A AbbVie terá a oportunidade de adquirir direitos exclusivos para desenvolver e comercializar até quatro inibidores de DUB selecionados, enquanto a Mission receberá uma taxa de licença inicial e pagamentos adicionais de marcos e royalties com base no sucesso dos compostos.
“A AbbVie é uma das principais empresas biofarmacêuticas do mundo, portanto, tê-las como nosso primeiro grande colaborador é uma grande validação da nossa ciência. Ele também marca um marco significativo em nosso objetivo estratégico de obter um pouco do valor de nossa expertise em DUB através de parcerias-chave do setor”, disse Anker Lundemose, MD, PhD, CEO da Mission.
"Juntos, podemos avançar no desenvolvimento da melhor plataforma de tecnologia DUB da Mission para encontrar tratamentos eficazes para essas doenças neurodegenerativas não atendidas", acrescentou.
A colaboração não inclui nenhum dos principais alvos da Mission, USP30 e USP10, que estão sob análise pré-clínica para o tratamento de vários distúrbios, incluindo doenças mitocondriais, doença de Parkinson e fibrose. Original em inglês, tradução Google, revisão Hugo. Fonte: Parkinson´s News Today. Leia aqui, sobre o PD1601, anticorpo monoclonal anti alfa-sinucleína da AbbVie. Leia mais aqui.
Mostrando postagens com marcador Mission Therapeutics. Mostrar todas as postagens
Mostrando postagens com marcador Mission Therapeutics. Mostrar todas as postagens
terça-feira, 27 de novembro de 2018
quinta-feira, 20 de abril de 2017
MJFF Grant Will Support Mission Therapeutics’ Test of Novel USP30 Therapy in Parkinson’s Models
APRIL 19, 2017 - MJFF Grant Will Support Mission Therapeutics’ Test of Novel USP30 Therapy in Parkinson’s Models
British pharmaceutical firm Mission Therapeutics will test its potent, selective USP30-targeted inhibitors in stem cell-derived Parkinson’s disease models, as part of research funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Cells maintain healthy mitochondria — the cell’s power generators — by degrading damaged mitochondria in a process known as mitophagy. Defective mitophagy has been linked to Parkinson’s disease. USP30, a deubiquitinase (DUB) located in the mitochondria, has been shown to control mitophagy under normal conditions. However, in neurons affected by Parkinson’s, altered USP30 signaling can lead to the toxic accumulation of mitochondria, which damages neuronal cells.
Mission Therapeutics has developed potent, selective inhibitors of USP30 and is exploring their potential for treating both Parkinson’s and cancer. Working with a research group led by University of Oxford Professor Richard Wade-Martins, the company will now test its USP30 inhibitors in induced pluripotent stem sells (iPSC) derived from patients with sporadic and familial Parkinson’s.
“USP30 is one of the more promising DUBs associated with mitophagy, in terms of published data and feasibility of compound development,” Shalini Padmanabhan, PhD, associate director of research programs at the New York-based MJFF, said in a press release. “We hope that this collaboration between Mission Therapeutics and Oxford Parkinson’s Disease Centre will promote our understanding of the mechanisms and consequences of USP30 inhibition in Parkinson’s disease.”
Neither the foundation nor the university disclosed the amount of MJFF’s grant.
“Receiving funding from the Michael J. Fox Foundation is a great accolade, recognizing the quality of the research being done by Mission Therapeutics and Prof. Wade-Martins and his group. The collaborative study will provide key data that will guide the clinical development strategy of our USP30 inhibitor program,” said Michael Koslowski, executive vice-president of research and development at Mission Therapeutics. “We are working hard to find new ways in which to tackle this difficult disease, which is especially highlighted during this World Parkinson Awareness week, for patients and their families.”
Parkinson’s is a long-term degenerative disorder of the central nervous system. No test or biomarker capable of identifying Parkinson’s is currently available, so the misdiagnosis rate can be substantially high. Recent estimates indicate that the disease affects nearly one million Americans, and more than five million people worldwide. Fonte: Parkinson News Today.
British pharmaceutical firm Mission Therapeutics will test its potent, selective USP30-targeted inhibitors in stem cell-derived Parkinson’s disease models, as part of research funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Cells maintain healthy mitochondria — the cell’s power generators — by degrading damaged mitochondria in a process known as mitophagy. Defective mitophagy has been linked to Parkinson’s disease. USP30, a deubiquitinase (DUB) located in the mitochondria, has been shown to control mitophagy under normal conditions. However, in neurons affected by Parkinson’s, altered USP30 signaling can lead to the toxic accumulation of mitochondria, which damages neuronal cells.
Mission Therapeutics has developed potent, selective inhibitors of USP30 and is exploring their potential for treating both Parkinson’s and cancer. Working with a research group led by University of Oxford Professor Richard Wade-Martins, the company will now test its USP30 inhibitors in induced pluripotent stem sells (iPSC) derived from patients with sporadic and familial Parkinson’s.
“USP30 is one of the more promising DUBs associated with mitophagy, in terms of published data and feasibility of compound development,” Shalini Padmanabhan, PhD, associate director of research programs at the New York-based MJFF, said in a press release. “We hope that this collaboration between Mission Therapeutics and Oxford Parkinson’s Disease Centre will promote our understanding of the mechanisms and consequences of USP30 inhibition in Parkinson’s disease.”
Neither the foundation nor the university disclosed the amount of MJFF’s grant.
“Receiving funding from the Michael J. Fox Foundation is a great accolade, recognizing the quality of the research being done by Mission Therapeutics and Prof. Wade-Martins and his group. The collaborative study will provide key data that will guide the clinical development strategy of our USP30 inhibitor program,” said Michael Koslowski, executive vice-president of research and development at Mission Therapeutics. “We are working hard to find new ways in which to tackle this difficult disease, which is especially highlighted during this World Parkinson Awareness week, for patients and their families.”
Parkinson’s is a long-term degenerative disorder of the central nervous system. No test or biomarker capable of identifying Parkinson’s is currently available, so the misdiagnosis rate can be substantially high. Recent estimates indicate that the disease affects nearly one million Americans, and more than five million people worldwide. Fonte: Parkinson News Today.
Assinar:
Postagens (Atom)